One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors
Filippo Crea
doi : 10.1093/eurheartj/ehab577
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3209–3213
Impact Factor of the European Heart Journal: update, interpretation, and perspectives
Filippo Crea
doi : 10.1093/eurheartj/ehab492
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3214–3215
The role of sex and gender differences in precision medicine: the work of the Women’s Brain Project
Annemarie Schumacher Dimech, Maria Teresa Ferretti, Else C Sandset, Antonella Santuccione Chadha
doi : 10.1093/eurheartj/ehab297
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3215–3217
Cardio Ultraefficient nanoParticles for Inhalation of Drug prOducts: when CUPIDO hits the nano-revolution in cardiology
Daniele Catalucci
doi : 10.1093/eurheartj/ehab266
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3217–3220
Interventional cardiology’s cross-departmental effort with production of reusable personal protective equipment during the early phase of COVID-19 pandemic
Sehrish Memon, Evan Friend, Jon C George, Sanjog Kalra
doi : 10.1093/eurheartj/ehab289
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3220–3223
Occluding to prevent occlusion
Giovanna Liuzzo, Carlo Patrono
doi : 10.1093/eurheartj/ehab464
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3224–3225
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria B?ck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno, Bernard Cosyns, Carolyn Crawford, Constantinos H Davos, Ileana Desormais, Emanuele Di Angelantonio, Oscar H Franco, Sigrun Halvorsen, F D Richard Hobbs, Monika Hollander, Ewa A Jankowska, Matthias Michal, Simona Sacco, Naveed Sattar, Lale Tokgozoglu, Serena Tonstad, Konstantinos P Tsioufis, Ineke van Dis, Isabelle C van Gelder, Christoph Wanner, Bryan Williams, ESC Scientific Document Group
doi : 10.1093/eurheartj/ehab484
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3227–3337
Persisting burden and challenges of rheumatic heart disease
Eloi Marijon, Ana Mocumbi, Kumar Narayanan, Xavier Jouven, David S Celermajer
doi : 10.1093/eurheartj/ehab407
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3338–3348
Rheumatic heart disease (RHD) is the result of episodes of acute rheumatic fever with valvular (and other cardiac) damage caused by an abnormal immune response to group A streptococcal infections, usually during childhood and adolescence. As a result of improved living conditions and the introduction of penicillin, RHD was almost eradicated in the developed world by the 1980s. However, being a disease of poverty, its burden remains disproportionately high in the developing world, despite being a fundamentally preventable disease. Rheumatic heart disease generates relatively little attention from the medical and science communities, in contrast to other common infectious problems (such as malaria, HIV, tuberculosis), despite the major cardiovascular morbidity/mortality burden imposed by RHD. This relative neglect and paucity of funding have probably contributed to limited fundamental medical advances in this field for over 50?years. Given the importance of prevention before the onset of major valvular damage, the main challenges for RHD prevention are improving social circumstances, early diagnosis, and effective delivery of antibiotic prophylaxis. Early identification through ultrasound of silent, subclinical rheumatic valve lesions could provide an opportunity for early intervention. Simple echocardiographic diagnostic criteria and appropriately trained personnel can be valuable aids in large-scale public health efforts. In addition, a better understanding of the immunogenic determinants of the disease may provide potential routes to vaccine development and other novel therapies.
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank
Sizhi Ai, Jihui Zhang, Guoan Zhao, Ningjian Wang, Guohua Li, Hon-Cheong So, Yaping Liu, Steven Wai-Ho Chau, Jie Chen, Xiao Tan, Fujun Jia, Xiangdong Tang, Jie Shi, Lin Lu, Yun-Kwok Wing
doi : 10.1093/eurheartj/ehab170
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3349–3357
Observational studies have suggested strong associations between sleep duration and many cardiovascular diseases (CVDs), but causal inferences have not been confirmed. We aimed to determine the causal associations between genetically predicted sleep duration and 12 CVDs using both linear and nonlinear Mendelian randomization (MR) designs.
Longer sleep improves cardiovascular outcomes: time to make sleep a priority
Tamar Sofer, Matthew O Goodman, Suzanne M Bertisch, Susan Redline
doi : 10.1093/eurheartj/ehab248
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3358–3360
Mammographic features are associated with cardiometabolic disease risk and mortality
Felix Grassmann, Haomin Yang, Mikael Eriksson, Shadi Azam, Per Hall, Kamila Czene
doi : 10.1093/eurheartj/ehab502
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3361–3370
In recent years, microcalcifications identified in routine mammograms were found to be associated with cardiometabolic disease in women. Here, we aimed to systematically evaluate the association of microcalcifications and other mammographic features with cardiometabolic disease risk and mortality in a large screening cohort and to understand a potential genetic contribution.
Mammograms to catch many birds with one stone
Angela H E M Maas, Pim A de Jong
doi : 10.1093/eurheartj/ehab522
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3371–3373
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study
Yuting Han, Yizhen Hu, Canqing Yu, Yu Guo, Pei Pei, Ling Yang, Yiping Chen, Huaidong Du, Dianjianyi Sun, Yuanjie Pang, Ningyu Chen, Robert Clarke, Junshi Chen, Zhengming Chen, Liming Li, Jun Lv, on behalf of the China Kadoorie Biobank Collaborative Group
doi : 10.1093/eurheartj/ehab413
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3374–3384
The potential difference in the impacts of lifestyle factors (LFs) on progression from healthy to first cardiometabolic disease (FCMD), subsequently to cardiometabolic multimorbidity (CMM), and further to death is unclear.
Key roles of five lifestyle risk factors in the harmful transition from a healthy condition to multimorbidity in the Chinese population
Dong Zhao
doi : 10.1093/eurheartj/ehab516
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3385–3387
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies
Min Seo Kim, Won Jun Kim, Amit V Khera, Jong Yeob Kim, Dong Keon Yon, Seung Won Lee, Jae Il Shin, Hong-Hee Won
doi : 10.1093/eurheartj/ehab454
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3388–3403
The aim of this study was to investigate the causal relationship and evidence of an association between increased adiposity and the risk of incident cardiovascular disease (CVD) events or mortality.
Obesity and cardiovascular health: the size of the problem
Annika Rosengren
doi : 10.1093/eurheartj/ehab518
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3404–3406
Clinical and methodological considerations when interpreting meta-analyses of beta-blocker use in patients with chronic obstructive pulmonary disease
Claudia Gulea, Jennifer K. Quint, Rosita Zakeri
doi : 10.1093/eurheartj/ehab217
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3407–3408
Increasing the prescription rate of ?-blockers is beneficial for patients with chronic obstructive pulmonary and cardiovascular disease
Yan-Li Yang, Zi-Jian Xiang, Ruo-Lan Xiang
doi : 10.1093/eurheartj/ehab239
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Page 3409
Bridging inflammation
Nicola Gaibazzi, Domenico Tuttolomondo, Damini Dey, Giampaolo Niccoli
doi : 10.1093/eurheartj/ehaa901
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Page 3384
Balloon pulmonary angioplasty with distal embolic protection device for chronic thromboembolic pulmonary hypertension
Ting-Ting Guo, Jiang-Shan Tan, Yan Wu, Xin Gao, Chao-Wu Yan, Shi-Guo Li, Lu Hua
doi : 10.1093/eurheartj/ehaa932
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Page 3408
Aortic intimo-intimal intussusception in Stanford type A acute aortic dissection
Aleksander Dokollari, Matteo Cameli, Louie Wang, Gianluigi Bisleri
doi : 10.1093/eurheartj/ehaa886
European Heart Journal, Volume 42, Issue 34, 7 September 2021, Page 3410
